GlycoEra Secures $130 Million in Series B Funding to Advance Autoimmune Disease Treatments
GlycoEra AG, a Swiss biotech firm, has raised $130 million in a Series B funding round led by Novo Holdings, with participation from several new and existing investors, to advance its innovative treatments for autoimmune diseases.
GlycoEra AG, a Swiss biotech company specializing in the development of extracellular protein degraders for autoimmune diseases, has successfully closed a $130 million Series B funding round. This significant financial boost was led by Novo Holdings, with contributions from a consortium of new and existing investors, including LifeArc Ventures, QIA, Agent Capital, MP Healthcare Venture Management, and Sixty Degree Capital, among others. The funding underscores the potential of GlycoEra's technology to revolutionize the treatment of autoimmune diseases by targeting and degrading pathogenic antibodies.
The proceeds from this funding round are earmarked for advancing GlycoEra's lead IgG4-targeted protein degrader into clinical trials, initiating a second program, and expanding its pipeline of precision extracellular degraders. CEO Ganesh Kaundinya highlighted the preclinical success of their lead program in rapidly degrading IgG4, a key player in autoimmune diseases, and the upcoming first-in-human clinical trials as pivotal steps toward delivering transformative therapies to patients.
This investment not only validates GlycoEra's scientific approach and platform but also accelerates its mission to address unmet needs in immunology and beyond. The involvement of high-profile investors and the addition of seasoned professionals to GlycoEra's board further bolster the company's position in the biotech landscape, promising significant advancements in the treatment of autoimmune diseases.